Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Two Representatives Introduce A Bipartisan Bill To The House Of Representatives

Mar 25, 2015 • 4:45 PM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The bipartisan bill introduced in the Senate earlier this month has gained support from important policy makers.

Yesterday, a similar bipartisan bill was introduced in the House of Representatives. The Compassionate Access, Research Expansion and Respect States (CARERS) Act was introduced by Democrat Steve Cohen (Tennessee) and Republican Don Young (Alaska). The purpose of the legislation is to reduce the federal government’s ability to crack down on state-legal medical marijuana programs and it aims to encourage more research into cannabis.

“The science has been in for a long time, and keeping marijuana on Schedule I — with heroin and LSD — is ludicrous,” Cohen said. “I am pleased to join with Congressman Don Young in introducing this important bill to bring the federal government in line with the science and the American people, respect states’ rights, remove the threat of federal prosecution in states with medical marijuana, and help our citizens access the treatments they need.”

The House bill contains six major policy changes

The House bill contains six key provisions. Those provisions are:

  1. Allow patients, doctors and businesses to participate in their state’s medical marijuana programs without fear of being prosecuted by the federal government.

  2. Reclassify marijuana as a less dangerous substance, moving it from Schedule I to Schedule II.

  3. Give veterans easier access to medical marijuana.

  4. Eliminate barriers to marijuana research.

  5. Remove low-THC strains of marijuana from the controlled substances list.

  6. Open up banking for marijuana businesses.

How does the Senate bill differ from the House bill?

The legislation that was introduced into the Senate had 5 key provisions; the House bill has 6. The additional provision is the removal of marijuana strains that are low-THC strains from the list of controlled substances.

Currently, 23 states and the District of Columbia have broad medical marijuana laws. Another 12 states have legalized cannabis strains that contain low-THC and high CBD. These states allow patients that suffer from certain debilitating conditions access to these strains.

The CARERS Act would remove marijuana with less than 0.3 percent THC from the CSA’s schedules altogether, allowing states to import low-THC/high-CBD strains for patients who need it.


Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.